Eli Lilly, Denovo Biopharma deal

Denovo acquired enzastaurin ( DB102) from Eli Lilly. In 2013, Lilly discontinued development of enzastaurin (formerly

Read the full 162 word article

How to gain access

Continue reading with a
two-week free trial.